Broken String Biosciences Closes $15M Series A Funding Round · Broken String Biosciences, a UK-based genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux…..
NIH clinical trial of universal flu vaccine candidate begins A colorized transmission electron micrograph of influenza A virus particles, colorized orange, isolated from a patient sample and then propagated in cell culture. ©NIAID Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at…..
AlveoGene to develop inhaled gene therapies for rare respiratory diseases AlveoGene is a new gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the UK Respiratory Gene Therapy Consortium (GTC). The Oxford-based company will use…..
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies • Major milestone achieved with new state-of-the-art microbiome facility spanning over 1600 m², completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe. • MaaT Pharma is…..
Advanced treatment for rare neurological “RASopathies” Parents’ initiative for affected children leads to a new EU research project RASopathies are a group of genetic diseases triggered by increased activation of the cellular RAS-MAPK signal pathway. This signal pathway has a decisive influence on growth and the differentiation of our cells.…..
Application of base editors in organoids opens new doors for cancer research The development of new cancer treatments depends on suitable tumor models in the laboratory. Researchers from the Organoid group (Hubrecht Institute) and the Princess Máxima Center have used base editors to simultaneously introduce multiple cancer-related mutations into healthy…..
Efficacy of gene therapy demonstrated in patients suffering from Crigler-Najjar Syndrome Crigler-Najjar syndrome is characterized by hyperbilirubinemia. If it is not treated quickly, the build-up of bilirubin, due to a deficiency in the liver enzyme UGT1A1, can cause significant neurological damage and become fatal. At the current time, the only…..
Novel nanocages for delivery of small interfering RNAs image:Schematic representation of the use of nanocages for siRNA delivery. When binding siRNA (arrow A), the nanocages with a typical diameter of 5-6 nanometre cluster into cage-RNA nanoparticles with a diameter of some 150 nanometres. This is small enough to enter a…..
Quantoom Biosciences is growing in Evry Quantoom Biosciences, a Belgian biotech dedicated to mRNA production and part of the global life science group Univercells, is opening a brand-new facility in Évry-Courcouronnes (France). Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but…..
Pierre Fabre to commercialize and distribute the first approved allogeneic T-cell immunotherapy in Europe Following transfer of the European Commission marketing authorization from Atara Biotherapeutics, Pierre Fabre is to lead launch and commercialization activities for Ebvallo® (tabelecleucel) in Europe The french group Pierre Fabre and Atara Biotherapeutics, a californian biotech…..
- 1
- 2
- 3
...
- 36
- Page Suivante
Partenaires
